Prous Institute: Speeding up the drug discovery and development process




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Prous Institute: Speeding up the drug discovery and development process
Released on: August 15, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    How much of a pharmaceutical candidate’s efficacy and safety can be predicted in silico, hence significantly speeding up the drug development process? Prous Institute for Biomedical Research is committed to discovering novel therapies for substantially unmet medical needs – namely oncology and CNS - by applying their expertise in computational science, synthetic chemistry, molecular and cellular biology, and pharmacology.
  • Summary
  • Transcript
  • Participants
  • Company
How much of a pharmaceutical candidate’s efficacy and safety can be predicted in silico, hence significantly speeding up the drug development process? Prous Institute for Biomedical Research is committed to discovering novel therapies for substantially unmet medical needs – namely oncology and CNS - by applying their expertise in computational science, synthetic chemistry, molecular and cellular biology, and pharmacology. Adrian Dawkes talks with their Vice President Josep Prous on the company’s technology, validated by big pharma and currently in active use for novel therapeutic development.
How much of a pharmaceutical candidate’s efficacy and safety can be predicted in silico, hence significantly speeding up the drug development process? Prous Institute for Biomedical Research is committed to discovering novel therapies for substantially unmet medical needs – namely oncology and CNS - by applying their expertise in computational science, synthetic chemistry, molecular and cellular biology, and pharmacology. Adrian Dawkes talks with their Vice President Josep Prous on the company’s technology, validated by big pharma and currently in active use for novel therapeutic development.
Josep Prous
How much of a pharmaceutical candidate’s efficacy and safety can be predicted in silico, hence significantly speeding up the drug development process? Prous Institute for Biomedical Research is committed to discovering novel therapies for substantially unmet medical needs – namely oncology and CNS - by applying their expertise in computational science, synthetic chemistry, molecular and cellular biology, and pharmacology. Adrian Dawkes talks with their Vice President Josep Prous on the company’s technology, validated by big pharma and currently in active use for novel therapeutic development.